Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Selective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposure.

Narayanan GA, Murray IA, Krishnegowda G, Amin S, Perdew GH.

J Pharmacol Exp Ther. 2012 Aug;342(2):345-55. doi: 10.1124/jpet.112.193482. Epub 2012 May 2.

2.

Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3',4'-dimethoxy-α-naphthoflavone.

Murray IA, Flaveny CA, Chiaro CR, Sharma AK, Tanos RS, Schroeder JC, Amin SG, Bisson WH, Kolluri SK, Perdew GH.

Mol Pharmacol. 2011 Mar;79(3):508-19. doi: 10.1124/mol.110.069369. Epub 2010 Dec 2.

3.

Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.

Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S, Schultz S, Kirschfink M.

Curr Cancer Drug Targets. 2010 Dec;10(8):922-31.

PMID:
20879979
4.

Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.

Zell S, Geis N, Rutz R, Schultz S, Giese T, Kirschfink M.

Clin Exp Immunol. 2007 Dec;150(3):576-84. Epub 2007 Sep 28.

5.

Cytokines affect resistance of human renal tumour cells to complement-mediated injury.

Blok VT, Gelderman KA, Tijsma OH, Daha MR, Gorter A.

Scand J Immunol. 2003 Jun;57(6):591-9.

6.

Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties.

Murray IA, Krishnegowda G, DiNatale BC, Flaveny C, Chiaro C, Lin JM, Sharma AK, Amin S, Perdew GH.

Chem Res Toxicol. 2010 May 17;23(5):955-66. doi: 10.1021/tx100045h.

7.

Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.

Spiller OB, Criado-García O, Rodríguez De Córdoba S, Morgan BP.

Clin Exp Immunol. 2000 Aug;121(2):234-41.

8.
9.

Complement gene expression is regulated by pro-inflammatory cytokines and the anaphylatoxin C3a in human tenocytes.

Busch C, Girke G, Kohl B, Stoll C, Lemke M, Krasnici S, Ertel W, Silawal S, John T, Schulze-Tanzil G.

Mol Immunol. 2013 Apr;53(4):363-73. doi: 10.1016/j.molimm.2012.09.001. Epub 2012 Oct 13.

PMID:
23070120
10.

Identification of a high-affinity ligand that exhibits complete aryl hydrocarbon receptor antagonism.

Smith KJ, Murray IA, Tanos R, Tellew J, Boitano AE, Bisson WH, Kolluri SK, Cooke MP, Perdew GH.

J Pharmacol Exp Ther. 2011 Jul;338(1):318-27. doi: 10.1124/jpet.110.178392. Epub 2011 Apr 14.

11.

Effect of periodontopathogen lipopolysaccharides and proinflammatory cytokines on CD46, CD55, and CD59 gene/protein expression by oral epithelial cells.

Mahtout H, Curt S, Chandad F, Rouabhia M, Grenier D.

FEMS Immunol Med Microbiol. 2011 Aug;62(3):295-303. doi: 10.1111/j.1574-695X.2011.00813.x. Epub 2011 Jun 8.

12.

Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells.

Hollingshead BD, Beischlag TV, Dinatale BC, Ramadoss P, Perdew GH.

Cancer Res. 2008 May 15;68(10):3609-17. doi: 10.1158/0008-5472.CAN-07-6168.

13.

Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity.

Murray IA, Morales JL, Flaveny CA, Dinatale BC, Chiaro C, Gowdahalli K, Amin S, Perdew GH.

Mol Pharmacol. 2010 Feb;77(2):247-54. doi: 10.1124/mol.109.061788. Epub 2009 Nov 10.

14.

Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation.

van Beek J, van Meurs M, 't Hart BA, Brok HP, Neal JW, Chatagner A, Harris CL, Omidvar N, Morgan BP, Laman JD, Gasque P.

J Immunol. 2005 Feb 15;174(4):2353-65.

15.

CD55 expression patterns on intestinal neuronal tissue are divergent from the brain.

Gelderman KA, Zijlmans HJ, Vonk MJ, Gorter A.

Gut. 2004 Apr;53(4):507-13.

16.

Mechanistic insights into the events that lead to synergistic induction of interleukin 6 transcription upon activation of the aryl hydrocarbon receptor and inflammatory signaling.

DiNatale BC, Schroeder JC, Francey LJ, Kusnadi A, Perdew GH.

J Biol Chem. 2010 Aug 6;285(32):24388-97. doi: 10.1074/jbc.M110.118570. Epub 2010 May 28.

17.

Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.

Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ.

Lab Invest. 1996 Jun;74(6):1039-49.

PMID:
8667608
18.

Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.

Rösner T, Lohse S, Peipp M, Valerius T, Derer S.

J Immunol. 2014 Aug 1;193(3):1485-95. doi: 10.4049/jimmunol.1400329. Epub 2014 Jun 27.

19.

Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.

Kwon YC, Kim H, Meyer K, Di Bisceglie AM, Ray R.

J Immunol. 2016 Aug 15;197(4):1127-36. doi: 10.4049/jimmunol.1600631. Epub 2016 Jun 29.

Supplemental Content

Support Center